0A9W.IL - Organon & Co.
| Previous close | 19.26 |
| Open | 19.05 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 18.96 - 19.06 |
| 52-week range | 18.96 - 38.01 |
| Volume | |
| Avg. volume | 1,718 |
| Market cap | 4.839B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 6.56 |
| EPS (TTM) | 2.89 |
| Earnings date | 04 May 2023 |
| Forward dividend & yield | 1.12 (5.82%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
Business WireOrganon Reports Results for the First Quarter Ended March 31, 2023
JERSEY CITY, N.J., May 04, 2023--Organon Reports Results for the First Quarter Ended March 31, 2023
ZacksAnalysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireOrganon To Report First Quarter and Host Conference Call on May 4, 2023
JERSEY CITY, N.J., April 20, 2023--Organon To Report First Quarter and Host Conference Call on May 4, 2023
Business WireOrganon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
JERSEY CITY, N.J., March 07, 2023--Organon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
Business WireOrganon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
JERSEY CITY, N.J., February 16, 2023--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2022.
Business WireOrganon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
JERSEY CITY, N.J., February 06, 2023--Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
ZacksWill Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Business WireOrganon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
JERSEY CITY, N.J., January 05, 2023--Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
Business WireOrganon To Present at the 41st Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., December 15, 2022--Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
Business WireOrganon Appoints Kirke Weaver as General Counsel and Corporate Secretary
JERSEY CITY, N.J., December 12, 2022--Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
Business WireOrganon To Present at the Piper Sandler 34th Annual Healthcare Conference
JERSEY CITY, N.J., November 15, 2022--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.
ACCESSWIREOrganon Announces Formal Commitment to FP2030 To Help Prevent 120 Million Unintended Pregnancies in Low- and Middle-Income Countries Around the World
Organon (NYSE:OGN), a global women's healthcare company, today announced its formal commitment to FP2030 to help prevent 120 million unintended pregnancies by 2030. Recognizing the urgency of the crisis, Organon is taking action to scale access to contraceptive options for more than 100 million women in low- and middle-income countries (LMICs), in addition to strategic partnerships focused on education, training, advocacy and youth engagement.
Business WireOrganon Reports Results for the Third Quarter Ended September 30, 2022
JERSEY CITY, N.J., November 03, 2022--Organon reports results for the third quarter ended September 30, 2022
Business WireOrganon To Report Third Quarter Results and Host Conference Call on November 3, 2022
JERSEY CITY, N.J., October 20, 2022--Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
Business WireSamsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
INCHEON, Korea & JERSEY CITY, N.J., August 17, 2022--Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
Simply Wall St.Organon (NYSE:OGN) Is Paying Out A Dividend Of $0.28
Organon & Co.'s ( NYSE:OGN ) investors are due to receive a payment of $0.28 per share on 15th of September. This means...
Business WireOrganon Reports Results for the Second Quarter Ended June 30, 2022
JERSEY CITY, N.J., August 04, 2022--Organon reports results for the second quarter ended June 30, 2022
Business WireOrganon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
JERSEY CITY, N.J., July 28, 2022--Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
- Simply Wall St.
What Kind Of Shareholders Hold The Majority In Organon & Co.'s (NYSE:OGN) Shares?
If you want to know who really controls Organon & Co. ( NYSE:OGN ), then you'll have to look at the makeup of its share...
Business WireOrganon To Report Second Quarter Results and Host Conference Call on August 4, 2022
JERSEY CITY, N.J., July 21, 2022--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company’s webcast and call scheduled for 8:30 a.m. EDT.
Business WireOrganon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
JERSEY CITY, N.J., June 13, 2022--Organon announces first biosimilars business deal with a global license agreement with Henlius.
- Simply Wall St.
Those who invested in Organon (NYSE:OGN) a year ago are up 37%
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...
Business WireOn One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
STOCKHOLM, June 02, 2022--Global women’s health company, Organon (NYSE: OGN), which employs 9,300 people globally, including 85 in its operations across the Nordics today announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report for 2021. The ESG report introduces the company’s ESG platform, known as Her Promise, and details how the company is working to help women and girls achieve the full potential of their promise through better health. The publication of